Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide or tirzepatide
Some medical providers prescribe it to support gut health and intestinal repair (BPC-157 is the primary peptide responsible for those effects.) The rest of the stack (TB-500, Thymosin Alpha-1, and GHK-Cu) can enhance or complement BPC-157s gut-healing benefits, but their roles are secondary.
Key Details Molecular Formula: CHNO Molecular Weight: 1419.55 g/mol CAS Number: 137525-51-0 Potential Research Applications 1
Relative metabolite abundance was calculated as the percentage of the total metabolite pool
At 2.4 mg weekly, average weight loss reached about 15% over 68 weeks. Response varied widely: 86% lost at least 5%, 69% lost 10%, half lost 15%, and about one-third lost 20%. These results describe that cohort rather than a universal forecast
Patient Reviews: Research online reviews (Google, Yelp) to gauge patient experiences
